UB Paderborn / Katalog / Suche / in CDI

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial

PloS one, 2013-12, Vol.8 (12), p.e79775-e79775

2013

Link zum Volltext

Verfügbarkeit prüfen

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

Modern pathology, 2016-10, Vol.29 (10), p.1155-1164

2016

Link zum Volltext

Verfügbarkeit prüfen

Sonographic Features of Triple‐Negative and Non–Triple‐Negative Breast Cancer

Journal of ultrasound in medicine, 2012-10, Vol.31 (10), p.1531-1541

2012

Link zum Volltext

Verfügbarkeit prüfen

FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results

Acta radiologica (1987), 2012-07, Vol.53 (6), p.628-636

2012

Link zum Volltext

Verfügbarkeit prüfen

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

BMC medicine, 2018-10, Vol.16 (1), p.179-179, Article 179

2018

Link zum Volltext

Verfügbarkeit prüfen

Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis

Annals of oncology, 2016-04, Vol.27 (4), p.608-618

2016

Link zum Volltext

Verfügbarkeit prüfen

MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer

Scientific reports, 2018-08, Vol.8 (1), p.11584-11, Article 11584

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival – Results from a prospective, observational study in Germany

Breast (Edinburgh), 2014-10, Vol.23 (5), p.603-608

2014

Link zum Volltext

Verfügbarkeit prüfen

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2011-09, Vol.22 (suppl_6), p.vi25-vi30

2011

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)

Annals of oncology, 2017-03, Vol.28 (3), p.651-657

2017

Link zum Volltext

Verfügbarkeit prüfen

Differential response of triple‐negative breast cancer to a docetaxel and carboplatin‐based neoadjuvant treatment

Cancer, 2010-09, Vol.116 (18), p.4227-4237

2010

Link zum Volltext

Verfügbarkeit prüfen

The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer

Annals of oncology, 2007-09, Vol.18 (9), p.1484-1492

2007

Link zum Volltext

Verfügbarkeit prüfen

Ready for a comeback of natural products in oncology

Biochemical pharmacology, 2009-05, Vol.77 (9), p.1447-1457

Bailly, Christian

2009

Link zum Volltext

Verfügbarkeit prüfen

mTOR inhibitors in breast cancer: A systematic review

Gynecologic oncology, 2012-12, Vol.127 (3), p.662-672

2012

Link zum Volltext

Verfügbarkeit prüfen

Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms

Oncogene, 2017-05, Vol.36 (20), p.2775-2790

2017

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate

British journal of cancer, 2003-05, Vol.88 (9), p.1339-1345

2003

Link zum Volltext

Verfügbarkeit prüfen

Integrating transcriptomics, proteomics, glycomics and glycoproteomics to characterize paclitaxel resistance in breast cancer cells

Journal of proteomics, 2021-07, Vol.243, p.104266, Article 104266

2021

Link zum Volltext

Verfügbarkeit prüfen

OSW‐1 inhibits tumor growth and metastasis by NFATc2 on triple‐negative breast cancer

Cancer medicine (Malden, MA), 2020-08, Vol.9 (15), p.5558-5569

2020

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience

The oncologist (Dayton, Ohio), 2004-06, Vol.9 (S2), p.24-32

2004

Link zum Volltext

Verfügbarkeit prüfen

Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer

Cancer management and research, 2019-01, Vol.11, p.727-739

2019

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience

SpringerPlus, 2014-07, Vol.3 (1), p.366-366, Article 366

2014

Link zum Volltext

Verfügbarkeit prüfen

Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy

European radiology, 2002-07, Vol.12 (7), p.1711-1719

2002

Link zum Volltext

Verfügbarkeit prüfen

Clinical development of mTOR inhibitors in breast cancer

Breast cancer research : BCR, 2014-02, Vol.16 (1), p.203-203, Article 203

2014

Link zum Volltext

Verfügbarkeit prüfen

Subjective and Objective Assessment of Edema during Adjuvant Chemotherapy for Breast Cancer Using Taxane-Containing Regimens in a Randomized Controlled Trial: The National Surgical Adjuvant Study of Breast Cancer 02

Oncology, 2012-01, Vol.82 (3), p.131-138

2012

Link zum Volltext

Verfügbarkeit prüfen

Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors

Molecular oncology, 2015-11, Vol.9 (9), p.1744-1759

2015

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

Sonographic Features of Triple‐Negative and Non–Triple‐Negative Breast Cancer

FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis

MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer

Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival – Results from a prospective, observational study in Germany

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC)

Differential response of triple‐negative breast cancer to a docetaxel and carboplatin‐based neoadjuvant treatment

The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer

Ready for a comeback of natural products in oncology

mTOR inhibitors in breast cancer: A systematic review

Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms

Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate

Integrating transcriptomics, proteomics, glycomics and glycoproteomics to characterize paclitaxel resistance in breast cancer cells

OSW‐1 inhibits tumor growth and metastasis by NFATc2 on triple‐negative breast cancer

Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience

Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer

Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience

Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy

Clinical development of mTOR inhibitors in breast cancer

Subjective and Objective Assessment of Edema during Adjuvant Chemotherapy for Breast Cancer Using Taxane-Containing Regimens in a Randomized Controlled Trial: The National Surgical Adjuvant Study of Breast Cancer 02

Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors

Aktive Filter

Suchergebnisse filtern